Logo image of BDRX

BIODEXA PHARMACEUTICALS-ADR (BDRX) Stock Fundamental Analysis

USA - NASDAQ:BDRX - US59564R8806 - ADR

5.4 USD
+0.11 (+2.08%)
Last: 11/7/2025, 5:22:55 PM
Fundamental Rating

2

BDRX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. The financial health of BDRX is average, but there are quite some concerns on its profitability. BDRX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year BDRX has reported negative net income.
BDRX had a negative operating cash flow in the past year.
In the past 5 years BDRX always reported negative net income.
BDRX had a negative operating cash flow in each of the past 5 years.
BDRX Yearly Net Income VS EBIT VS OCF VS FCFBDRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

The Return On Assets of BDRX (-42.01%) is comparable to the rest of the industry.
BDRX has a Return On Equity of -54.45%. This is in the better half of the industry: BDRX outperforms 64.04% of its industry peers.
Industry RankSector Rank
ROA -42.01%
ROE -54.45%
ROIC N/A
ROA(3y)-81.49%
ROA(5y)-102.56%
ROE(3y)-154.1%
ROE(5y)-168.96%
ROIC(3y)N/A
ROIC(5y)N/A
BDRX Yearly ROA, ROE, ROICBDRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BDRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BDRX Yearly Profit, Operating, Gross MarginsBDRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -2K -4K -6K

More info and screens

5

2. Health

2.1 Basic Checks

BDRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
BDRX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, BDRX has more shares outstanding
The debt/assets ratio for BDRX is higher compared to a year ago.
BDRX Yearly Shares OutstandingBDRX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 50K 100K 150K
BDRX Yearly Total Debt VS Total AssetsBDRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of -10.50, we must say that BDRX is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of BDRX (-10.50) is worse than 73.03% of its industry peers.
BDRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -10.5
ROIC/WACCN/A
WACC8.29%
BDRX Yearly LT Debt VS Equity VS FCFBDRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M

2.3 Liquidity

A Current Ratio of 3.63 indicates that BDRX has no problem at all paying its short term obligations.
The Current ratio of BDRX (3.63) is comparable to the rest of the industry.
A Quick Ratio of 3.63 indicates that BDRX has no problem at all paying its short term obligations.
BDRX has a Quick ratio (3.63) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.63
Quick Ratio 3.63
BDRX Yearly Current Assets VS Current LiabilitesBDRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

BDRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 98.57%, which is quite impressive.
The Revenue for BDRX has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)98.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.4%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 12.21% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y33.34%
EPS Next 2Y11.8%
EPS Next 3Y12.21%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BDRX Yearly Revenue VS EstimatesBDRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2027 2M 4M 6M 8M
BDRX Yearly EPS VS EstimatesBDRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2023 2024 2025 2026 2027 -50 -100 -150

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BDRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BDRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BDRX Price Earnings VS Forward Price EarningsBDRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BDRX Per share dataBDRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20 -20

4.3 Compensation for Growth

A more expensive valuation may be justified as BDRX's earnings are expected to grow with 12.21% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.8%
EPS Next 3Y12.21%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BDRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIODEXA PHARMACEUTICALS-ADR

NASDAQ:BDRX (11/7/2025, 5:22:55 PM)

5.4

+0.11 (+2.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)09-12 2025-09-12
Earnings (Next)N/A N/A
Inst Owners6.25%
Inst Owner Change-53.84%
Ins Owners0.39%
Ins Owner ChangeN/A
Market Cap3.35M
Revenue(TTM)N/A
Net Income(TTM)-6.23M
Analysts85.71
Price Target183.6 (3300%)
Short Float %4.46%
Short Ratio0.17
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)900%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.22
P/tB 0.44
EV/EBITDA N/A
EPS(TTM)-27.77
EYN/A
EPS(NY)-3.85
Fwd EYN/A
FCF(TTM)-23.37
FCFYN/A
OCF(TTM)-22.74
OCFYN/A
SpS0
BVpS24.17
TBVpS12.24
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -42.01%
ROE -54.45%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-81.49%
ROA(5y)-102.56%
ROE(3y)-154.1%
ROE(5y)-168.96%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 114.73%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.63
Quick Ratio 3.63
Altman-Z -10.5
F-Score3
WACC8.29%
ROIC/WACCN/A
Cap/Depr(3y)138.58%
Cap/Depr(5y)102.46%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)98.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.4%
EPS Next Y33.34%
EPS Next 2Y11.8%
EPS Next 3Y12.21%
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-12.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-48.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-45.58%
OCF growth 3YN/A
OCF growth 5YN/A

BIODEXA PHARMACEUTICALS-ADR / BDRX FAQ

What is the fundamental rating for BDRX stock?

ChartMill assigns a fundamental rating of 2 / 10 to BDRX.


What is the valuation status for BDRX stock?

ChartMill assigns a valuation rating of 0 / 10 to BIODEXA PHARMACEUTICALS-ADR (BDRX). This can be considered as Overvalued.


What is the profitability of BDRX stock?

BIODEXA PHARMACEUTICALS-ADR (BDRX) has a profitability rating of 1 / 10.


What is the financial health of BIODEXA PHARMACEUTICALS-ADR (BDRX) stock?

The financial health rating of BIODEXA PHARMACEUTICALS-ADR (BDRX) is 5 / 10.